Popular topics to explore
Lupin faces pressure as Citi turns bearish
LUPIN shares came under pressure on August 27 after falling as much as 1.8% to a six-month low, before recovering most of the losses during afternoon trade. The stock was trading around ₹2,184, nearly flat from the previous close. The weak…
Lupin Ltd. Investment Update: Divergent Analyst Perspectives
LUPIN
Executive Summary
Lupin Ltd. experienced a 2% decline in early trading on August 27, 2026, following a prominent downgrade. The stock, down approximately 9% YTD, currently presents a complex investment profile characterized by confl…
Lupin - A failed Rounding bottom Breakout - Trapped Investor
LUPIN is showing a failed breakout setup on the daily chart after briefly moving above the important ₹2,420 resistance zone but failing to sustain the breakout. The stock extended its move toward ₹2,500–2,520 before facing sharp profit bo…
Lupin Secures USFDA Approval for Generic Pitolisant
Lupin Limited has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. Determined to be bioequivalent…
Can GLP-1 drugs change India’s productivity story?
A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increas…
24th Aug · SEBI-Registered Analyst
Algobazar- Data driven Wealth Management · 24th Aug
Daily Index View : BANKNIFTY as on 24/08/2026
1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -10% 🔍 Key Level to Watch: 57430 🔄 Current Market Surface: The trend will stay Positive until the market stay above 57430 That’s 332 points away from the las…
Lupin Expands European Ophthalmology Business with YUVEZZI Commercialisation Deal
Lupin Ltd has strengthened its specialty ophthalmology portfolio after its wholly owned subsidiary VISUfarma B.V. entered into an exclusive licensing agreement with Visus Therapeutics, a subsidiary of Tenpoint Therapeutics, to commercialise…
DEVIT
**Order Win & Strategic Licensing Deal**
** DEVIT :** Secured a **₹5.15 crore** order from **NICSI** for development of **IFMS 3.0 web and mobile applications**, with project execution expected to be completed in around **6 months**.
**I…
LUPIN
LUPIN LIMITED: CO. ENTERS EXCLUSIVE LICENSE AGREEMENT WITH VISUS THERAPEUTICS FOR YUVEZZITM IN EUROPE; TOTAL POTENTIAL CONSIDERATION UP TO €75 MILLION INCLUDING STRATEGIC INVESTMENT AND MILESTONE PAYMENTS.
Lupin Enters Exclusive License Deal with Visus for YUVEZZI in Europe, Up to €75 Mn
LUPIN Limited has entered into an exclusive license agreement with Visus Therapeutics (part of Tenpoint Therapeutics) for YUVEZZI™, a proprietary ophthalmic product for treating presbyopia in adults, covering Europe, the UK, Switzerland a…
20th Aug · SEBI-Registered Analyst
Algobazar- Data driven Wealth Management · 20th Aug
Daily Index View : NIFTY50 as on 20/08/2026
1. Market Trend PROBABILITY 🚨 Current Market Trend: Positive 🚀 -10% 🔍 Key Level to Watch: 24276 🔄 Current Market Surface: The trend will stay Positive until the market stay above 24276 That’s 197 points away from the las…
Update for investors of Lupin
LUPIN is currently trading at Rs. 2260.35, up by 25.35 points or 1.13% from its previous closing of Rs. 2235.00 on the BSE.
The scrip opened at Rs. 2225.50 and has touched a high and low of Rs. 2,265.45 and Rs. 2219.75 respectively. So f…
India’s Drug Law Is Changing: Who Could Benefit?
Imagine a drug factory operating for more than a decade, while the central regulator doesn’t even have it properly recorded in its database. That is the bigger problem with India’s old drug-regulation system: fragmentation, weak informatio…
India’s 86-Year-Old Drug Law Is Finally Being Rewritten
Imagine buying a medicine for a child and assuming one thing: the system has already checked it. Recent cough-syrup tragedies showed why that assumption cannot always be taken for granted. India’s 1940 Drugs and Cosmetics Act is now 86 yea…
Sun Pharma Faces Delhi HC Hurdle on Semaglutide Tablet Launch Amid Novo Patent Plea
The Delhi High Court has directed Sun Pharma Laboratories to seek its prior approval before commercially launching semaglutide tablets. The order follows Novo Nordisk’s patent infringement plea concerning the oral formulation of the diab…
Lupin Strengthens US Portfolio as Q1 FY27 Delivers Strong Growth
Lupin Ltd has received US FDA approval for its Sodium Zirconium Cyclosilicate Oral Suspension in 5 g/packet and 10 g/packet strengths, a generic equivalent to AstraZeneca’s Lokelma, indicated for treating hyperkalemia in adults. The product…
WATCH OUT FOR STOCKS IN NEWS
Watch out for the below mentioned stocks in news which are likely to be on spotlight for today the 11-Aug-2026 : - Mahindra and Mahindra: The homegrown automajor's production volume grew 20.4 per cent YoY to 1,01,954 units in June 2026, wh…
LUPIN
**USFDA Approval, Defence Order & Expansion**
** LUPIN :** Received **U.S. FDA approval** for **Sodium Zirconium Cyclosilicate for Oral Suspension** in the United States.
**Impact:** **Positive;** expands Lupin's U.S. product portfolio a…
Pre Market Report & Global Cues| 11 Aug
Global cues are slightly weak. US markets closed a bit lower. Nothing major, but US 10Y yield has moved up to ~4.7%. More important, crude jumped to $88 after a sharp move yesterday. That’s something to watch. Asian markets are mixed. Jap…
Lupin Q1 FY27 Concall: Record Quarter, Strong Pipeline and US Growth Opportunities
Key Highlights Lupin delivered a record Q1 FY27, with strong revenue and EBITDA growth. Management highlighted continued momentum in India, a robust US pipeline, and multiple medium-term growth opportunities, while cautioning that Q1 margi…
